注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Pieris Pharmaceuticals Inc是一家臨床階段的生物技術公司,致力於發現和開發基於Anticain的藥物,以針對經過驗證的疾病途徑。該公司的臨床產品線包括用於治療哮喘的吸入IL-4Rα拮抗劑Anticin蛋白,免疫腫瘤學(IO),靶向HER2和4-1BB的雙特異性,以及靶向PD-L1和4-1BB的IO雙特異性靶向PD-L1和4-1BB。其基於鉛呼吸安提卡林的候選藥物PRS-060 / AZD1402拮抗IL-4R α,從而抑制IL-4和IL-13這兩種細胞因子,這兩種細胞因子是介導人體內細胞之間信號傳導的小蛋白質,已知是炎症級聯反應中的介質,可驅動哮喘和其他炎症性疾病的發病機制。其管道中基於前IO抗提菌素的候選藥物cinrebafuspα,其設計用於靶向免疫受體4-1BB和腫瘤靶向HER2。Cinrebafusp alfa是HER2靶向抗體與Anticin蛋白的變體的遺傳融合。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Stephen S. Yoder | 47 | 2010 | CEO, President & Director |
Bruce Levy | - | - | Member of Clinical & Scientific Advisory Board |
Michael S. Richman | 62 | 2014 | Independent Director |
Peter Barnes | - | - | Member of Clinical & Scientific Advisory Board |
Padmanee Sharma | - | - | Member of Clinical & Scientific Advisory Board |
Vijay Kumar Kuchroo | 68 | - | Member of Clinical & Scientific Advisory Board |
Christopher P. Kiritsy | 58 | 2016 | Independent Director |
Peter A. Kiener | 71 | 2018 | Independent Director |
Ian Adcock | - | - | Member of Clinical & Scientific Advisory Board |
Gary Anderson | - | - | Member of Clinical & Scientific Advisory Board |
Dario A. Vignali | - | - | Member of Clinical & Scientific Advisory Board |
Matthew L. Sherman | 67 | 2018 | Independent Director |
Oliver Eickelberg | - | - | Member of Clinical & Scientific Advisory Board |
James Arthur Geraghty | 68 | 2017 | Independent Chairman |
Maya R. Said | 46 | 2019 | Independent Director |
David Schwartz | - | - | Member of Clinical & Scientific Advisory Board |
E. John Werry | - | - | Member of Clinical & Scientific Advisory Board |
Michael A. Curran | - | - | Member of Clinical & Scientific Advisory Board |
Ann Barbier | 59 | 2018 | Independent Director |
Fan Chung | - | - | Member of Clinical & Scientific Advisory Board |
Sally Wenzel | - | - | Member of Clinical & Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核